Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral ther… Read more
Shandong Kexing Bioproducts Co. Ltd. A (688136) - Total Assets
Latest total assets as of September 2025: CN¥3.41 Billion CNY
Based on the latest financial reports, Shandong Kexing Bioproducts Co. Ltd. A (688136) holds total assets worth CN¥3.41 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Kexing Bioproducts Co. Ltd. A - Total Assets Trend (2017–2024)
This chart illustrates how Shandong Kexing Bioproducts Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Kexing Bioproducts Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Kexing Bioproducts Co. Ltd. A's total assets of CN¥3.41 Billion consist of 40.7% current assets and 59.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.5% |
| Accounts Receivable | CN¥579.72 Million | 18.3% |
| Inventory | CN¥141.81 Million | 4.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥256.02 Million | 8.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shandong Kexing Bioproducts Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Kexing Bioproducts Co. Ltd. A's current assets represent 40.7% of total assets in 2024, a decrease from 50.4% in 2017.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, up from 8.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 3.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 18.3% of total assets.
Shandong Kexing Bioproducts Co. Ltd. A Competitors by Total Assets
Key competitors of Shandong Kexing Bioproducts Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shandong Kexing Bioproducts Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shandong Kexing Bioproducts Co. Ltd. A generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shandong Kexing Bioproducts Co. Ltd. A generates $ 1.00 in net profit.
Shandong Kexing Bioproducts Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 1.47 | 3.73 |
| Quick Ratio | 1.38 | 1.29 | 3.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥517.43 Million | CN¥ 360.16 Million | CN¥ 1.20 Billion |
Shandong Kexing Bioproducts Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shandong Kexing Bioproducts Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.55 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | CN¥3.16 Billion |
| Market Capitalization | $387.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Kexing Bioproducts Co. Ltd. A's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Kexing Bioproducts Co. Ltd. A's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Kexing Bioproducts Co. Ltd. A (2017–2024)
The table below shows the annual total assets of Shandong Kexing Bioproducts Co. Ltd. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.16 Billion | +4.33% |
| 2023-12-31 | CN¥3.03 Billion | -4.04% |
| 2022-12-31 | CN¥3.16 Billion | +11.65% |
| 2021-12-31 | CN¥2.83 Billion | +19.54% |
| 2020-12-31 | CN¥2.37 Billion | +100.56% |
| 2019-12-31 | CN¥1.18 Billion | +38.12% |
| 2018-12-31 | CN¥854.33 Million | +14.95% |
| 2017-12-31 | CN¥743.20 Million | -- |